Evidence and Value of Prescription Omega-3 Fatty Acids in Cardiovascular Disease Management
Host: Deepak L. Bhatt, MD, MPH, Chair
Guest: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Daniel E. Hilleman, PharmD, FCCP
Despite the success of statin therapy in significantly reducing patients’ LDL-cholesterol and the risk of cardiovascular events, there remains a considerable need for event reduction. Fortunately, we now have findings from the REDUCE-IT landmark trial on icosapent ethyl that could help us find a way to meet that need.
This activity will provide practical information on the evidence, clinical utility, and use of icosapent ethyl in patients at risk of ASCVD events.